Results 241 to 250 of about 51,921 (307)
We provide the first evidence that pronounced release of DAO during anaphylaxis is restricted to patients with clonal mast cell disorder. This finding offers possible functional support for the reported association between KIT p.D816V and anaphylaxis severity.
Matija Rijavec +5 more
wiley +1 more source
Autoimmune Mechanisms and Extracellular Traps in Non-eosinophilic Asthma. [PDF]
Hur GY.
europepmc +1 more source
Dupilumab reduces patient-reported cough and improves quality of life in patients with severe eosinophilic asthma with or without chronic rhinosinusitis with nasal polyps: a real-life prospective study. [PDF]
Lombardi C +3 more
europepmc +1 more source
Algorithms of Patient Selection for Allergen Immunotherapy
Allergy, EarlyView.
U. Petra Zieglmayer +5 more
wiley +1 more source
Real-World Effectiveness and Safety of Mepolizumab in Severe Eosinophilic Asthma: Insights From the Korean Severe Asthma Registry (KoSAR). [PDF]
Park SY +15 more
europepmc +1 more source
Early and Sustained Response to Benralizumab in Severe, Eosinophilic Asthma: A Real-World Observational Study. [PDF]
Stolz D +8 more
europepmc +1 more source
Stellate Ganglion Block and Bilateral Sympathectomy for Recurrent Coronary Vasospasm Secondary to Severe Eosinophilic Asthma. [PDF]
Wu KY +9 more
europepmc +1 more source
Clinical &Experimental Allergy, Volume 55, Issue 3, Page 253-255, March 2025.
Robert Greig +4 more
wiley +1 more source

